Clip CAR T and Converter CAR T therapy biotech animation - Mode of Action

TiCARos (ticaros.com) was our first South Korean (Seoul) Biotech startup customer. TiCARos is specializing in enhanced T cell therapies and owns 2 platforms, the CLIP CAR and the CONVERTER CAR platform - next-generation immunotherapeutics for cancers.

CONVERTER CAR technique of TiCARos enables selective inhibition of CTLA4 only in tumor-specific CAR-T cells without affecting other T cells in patient’s blood.

We have produced this Mode of Action video in a what we call 2D medical style, focusing on the key message. The target of this video was to explain the CAR therapies in an easy-to-understand video format.

Explanatory videos like this Mode of Action video help explain science and spark interest among investors, partners, and the public.

The process of producing such a video is straight-forward and consists of a script, storyboard, design proposal, animation, recording of the voice-over for the video.

Contact us to find out more: life-science-animation.com!

Here is the script of the video:
CAR-T therapy is a promising novel approach to treat cancer.
The patient’s T cells are engineered with chimeric antigen receptors (CAR) …
… to better recognize and kill tumor cells.
However, the anti-tumor activity of CAR-T cells …
… is often limited by the immunosuppressive tumor microenvironment.
TiCARos, a Korean biotech company, develops proprietary technologies to address current therapeutic limitations by enhancing the tumor-killing efficacy of CAR-T cells,...
… including Converter-CAR and CLIP-CAR.
In conventional CAR-T, the T cell receives activating signals from CD28, …
… but also inhibitory signals from the immune-checkpoint receptor, CTLA4.
As a result, the tumor-killing T cells may not become fully activated.
Ticaros’ Converter-CAR converts the inhibitory signal of CTLA4 to an activating signal of CD28.
This is achieved by delivering CTC28 together with the CAR molecule.
In CTC28, the intracellular domain of CTLA4 has been replaced with the intracellular domain of CD28.
CTC28 competes with endogenous CTLA4, …
... enhancing the activation signal, and thereby the anti-tumor capacity.
Another limiting factor in current CAR-T therapies is that CAR-T cells often do not bind stably to tumor cells, …
… so tumor cells cannot be efficiently killed.
CLIP-CAR T …
… uses a modified proprietary CAR molecule containing TiCARos’ unique transmembrane domain …
… to stabilize the contact sites between T cells and tumor cells, also called immune synapses.
The increased binding stability of CLIP-CAR T to tumor cells boosts CAR-T activation and proliferation, further increasing the tumor-killing potency of CAR-T cells.
In vivo studies have confirmed an increased efficacy of the CONVERTER-CAR and CLIP-CAR technologies compared to standard CAR-therapies.
Learn more at ticaros.com

Видео Clip CAR T and Converter CAR T therapy biotech animation - Mode of Action канала Life Science Animation